
Sign up to save your podcasts
Or


A.M. Edition for Feb. 9. The latest revelations from the Epstein files bring down the top aide to Britain’s prime minister. Will Keir Starmer be next? WSJ U.K. correspondent Max Colchester weighs in. Plus, Novo Nordisk shares are rallying after the U.S. Food and Drug Administration threatened to restrict access to the ingredients needed for knockoffs of popular GLP-1 medicines like Wegovy. And SpaceX delays its Mars plans to focus on the moon instead. Luke Vargas hosts.
Sign up for the WSJ’s free What’s News newsletter.
Learn more about your ad choices. Visit megaphone.fm/adchoices
By The Wall Street Journal4.1
40734,073 ratings
A.M. Edition for Feb. 9. The latest revelations from the Epstein files bring down the top aide to Britain’s prime minister. Will Keir Starmer be next? WSJ U.K. correspondent Max Colchester weighs in. Plus, Novo Nordisk shares are rallying after the U.S. Food and Drug Administration threatened to restrict access to the ingredients needed for knockoffs of popular GLP-1 medicines like Wegovy. And SpaceX delays its Mars plans to focus on the moon instead. Luke Vargas hosts.
Sign up for the WSJ’s free What’s News newsletter.
Learn more about your ad choices. Visit megaphone.fm/adchoices

2,846 Listeners

1,719 Listeners

430 Listeners

1,648 Listeners

113,272 Listeners

686 Listeners

1,450 Listeners

1,044 Listeners

9,721 Listeners

1,316 Listeners

6,102 Listeners

1,574 Listeners

1,322 Listeners

586 Listeners

151 Listeners

88 Listeners

82 Listeners

151 Listeners